Clinical trial
A 12-week, Open-label, Dose-escalating, Phase 2 Study to Evaluate the Effects of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
NCT02472535 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 12-week, Open-label, Dose-escalating, Phase 2 Study to Evaluate the Effects of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
- Lead sponsor
- Gilead Sciences
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2015
- Completion date
- February 29, 2016
- Enrollment
- 13 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.